Last reviewed · How we verify

NCT06749678

Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma

Not yet recruiting NA Last updated 27 December 2024
What this trial tests

NA trial testing Prehabilitation in Advanced Hepatocellular Carcinoma (HCC) in 84 participants. Not yet recruiting.

Timeline
1 January 2025
Primary endpoint
1 January 2027
1 June 2027

Quick facts

Lead sponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment84
Start date1 January 2025
Primary completion1 January 2027
Estimated completion1 June 2027
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Who can join

Adults 18 to 75, any sex, with Advanced Hepatocellular Carcinoma (HCC) or Prehabilitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, randomised controlled clinical trial to study the impact of prehabilitation on postoperative complications, physical function, quality of life, and short-term survival outcomes in patients with unresectable liver cancer undergoing conversion therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Prehabilitation

Trials testing the same drug.

Other recruiting trials for Advanced Hepatocellular Carcinoma (HCC)

Currently open trials in the same condition.

Other Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06749678.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing